Previously, bortezomib-induced downregulation of HLA-class I [47], KIR-blockade with IPH2101 [48] and HLA-blockade with W6/32 [16] have been shown to enhance killing of myeloma cells by NK cells. This evidence concerns the gene KIR3DL1 and plasma cell myeloma.